| Literature DB >> 6132932 |
Abstract
This article reviews the clinical literature of flurazepam, temazepam, and triazolam. The long half-life drug flurazepam and the short half-life drug triazolam produced similar results in terms of clinical improvement and adverse effects when equivalent dosages were administered. Temazepam, in the present U.S. formulation, appeared to be less effective in sleep latency than the other two compounds.Entities:
Mesh:
Substances:
Year: 1983 PMID: 6132932
Source DB: PubMed Journal: J Clin Psychopharmacol ISSN: 0271-0749 Impact factor: 3.153